S&P 500   4,378.18 (-0.72%)
DOW   34,366.07 (+0.00%)
QQQ   347.43 (-1.66%)
AAPL   160.27 (-0.84%)
MSFT   291.82 (-1.54%)
FB   304.10 (-1.49%)
GOOGL   2,569.62 (-1.78%)
AMZN   2,810.00 (-2.80%)
TSLA   927.66 (-0.25%)
NVDA   226.19 (-3.22%)
BABA   119.36 (-0.84%)
NIO   23.97 (-3.62%)
AMD   112.49 (-3.47%)
CGC   7.32 (-1.08%)
MU   81.59 (-1.64%)
GE   91.02 (-6.08%)
T   26.40 (+0.23%)
F   19.95 (-2.16%)
DIS   136.32 (-0.83%)
AMC   16.36 (-1.68%)
PFE   52.68 (+2.21%)
ACB   4.19 (-3.01%)
BA   203.21 (-0.48%)
S&P 500   4,378.18 (-0.72%)
DOW   34,366.07 (+0.00%)
QQQ   347.43 (-1.66%)
AAPL   160.27 (-0.84%)
MSFT   291.82 (-1.54%)
FB   304.10 (-1.49%)
GOOGL   2,569.62 (-1.78%)
AMZN   2,810.00 (-2.80%)
TSLA   927.66 (-0.25%)
NVDA   226.19 (-3.22%)
BABA   119.36 (-0.84%)
NIO   23.97 (-3.62%)
AMD   112.49 (-3.47%)
CGC   7.32 (-1.08%)
MU   81.59 (-1.64%)
GE   91.02 (-6.08%)
T   26.40 (+0.23%)
F   19.95 (-2.16%)
DIS   136.32 (-0.83%)
AMC   16.36 (-1.68%)
PFE   52.68 (+2.21%)
ACB   4.19 (-3.01%)
BA   203.21 (-0.48%)
S&P 500   4,378.18 (-0.72%)
DOW   34,366.07 (+0.00%)
QQQ   347.43 (-1.66%)
AAPL   160.27 (-0.84%)
MSFT   291.82 (-1.54%)
FB   304.10 (-1.49%)
GOOGL   2,569.62 (-1.78%)
AMZN   2,810.00 (-2.80%)
TSLA   927.66 (-0.25%)
NVDA   226.19 (-3.22%)
BABA   119.36 (-0.84%)
NIO   23.97 (-3.62%)
AMD   112.49 (-3.47%)
CGC   7.32 (-1.08%)
MU   81.59 (-1.64%)
GE   91.02 (-6.08%)
T   26.40 (+0.23%)
F   19.95 (-2.16%)
DIS   136.32 (-0.83%)
AMC   16.36 (-1.68%)
PFE   52.68 (+2.21%)
ACB   4.19 (-3.01%)
BA   203.21 (-0.48%)
S&P 500   4,378.18 (-0.72%)
DOW   34,366.07 (+0.00%)
QQQ   347.43 (-1.66%)
AAPL   160.27 (-0.84%)
MSFT   291.82 (-1.54%)
FB   304.10 (-1.49%)
GOOGL   2,569.62 (-1.78%)
AMZN   2,810.00 (-2.80%)
TSLA   927.66 (-0.25%)
NVDA   226.19 (-3.22%)
BABA   119.36 (-0.84%)
NIO   23.97 (-3.62%)
AMD   112.49 (-3.47%)
CGC   7.32 (-1.08%)
MU   81.59 (-1.64%)
GE   91.02 (-6.08%)
T   26.40 (+0.23%)
F   19.95 (-2.16%)
DIS   136.32 (-0.83%)
AMC   16.36 (-1.68%)
PFE   52.68 (+2.21%)
ACB   4.19 (-3.01%)
BA   203.21 (-0.48%)
NASDAQ:TERN

Terns Pharmaceuticals Stock Forecast, Price & News

$5.60
-0.15 (-2.61%)
(As of 01/25/2022 01:40 PM ET)
Add
Compare
Today's Range
$5.45
$5.73
50-Day Range
$5.65
$8.82
52-Week Range
$5.36
$28.36
Volume
1,551 shs
Average Volume
63,749 shs
Market Capitalization
$141.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive TERN News and Ratings via Email

Sign-up to receive the latest news and ratings for Terns Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Terns Pharmaceuticals logo

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California.

Headlines

Terns Pharmaceuticals, Inc. Common Stock (TERN)
January 14, 2022 |  nasdaq.com
Should I Avoid Terns Pharmaceuticals, Inc. (TERN)?
October 4, 2021 |  finance.yahoo.com
Terns Pharmaceuticals, Inc.(TERN)
September 16, 2021 |  fool.com
Goldman Sachs Sees These 2 Stocks Surging Over 70%
September 15, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TERN
Phone
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Net Income
$-40.05 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$141.50 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
1/25/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

774th out of 1,416 stocks

Pharmaceutical Preparations Industry

373rd out of 684 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Terns Pharmaceuticals (NASDAQ:TERN) Frequently Asked Questions

Is Terns Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Terns Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Terns Pharmaceuticals stock.
View analyst ratings for Terns Pharmaceuticals
or view top-rated stocks.

When is Terns Pharmaceuticals' next earnings date?

Terns Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Terns Pharmaceuticals
.

How were Terns Pharmaceuticals' earnings last quarter?

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) posted its earnings results on Monday, November, 15th. The company reported ($0.47) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.64) by $0.17.
View Terns Pharmaceuticals' earnings history
.

What price target have analysts set for TERN?

3 brokerages have issued 1-year target prices for Terns Pharmaceuticals' shares. Their forecasts range from $21.00 to $32.00. On average, they expect Terns Pharmaceuticals' share price to reach $26.50 in the next year. This suggests a possible upside of 373.2% from the stock's current price.
View analysts' price targets for Terns Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Terns Pharmaceuticals' key executives?

Terns Pharmaceuticals' management team includes the following people:
  • Mr. Senthil Vel Sundaram, CEO & Director (Age 43, Pay $581.77k)
  • Dr. Erin Quirk M.D., Head of R&D, Pres & Chief Medical Officer (Age 50, Pay $549.39k)
  • Dr. Weidong Zhong Ph.D., Co-Founder, Director & Chief Scientific Officer (Age 55)
  • Dr. Mark Joseph Vignola, CFO & Treasurer (Age 43, Pay $402.15k)
  • Mr. Seokho Yoon Esq., COO, Gen. Counsel & Sec. (Age 43)

When did Terns Pharmaceuticals IPO?

(TERN) raised $101 million in an IPO on Friday, February 5th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO.

What is Terns Pharmaceuticals' stock symbol?

Terns Pharmaceuticals trades on the NASDAQ under the ticker symbol "TERN."

Who are Terns Pharmaceuticals' major shareholders?

Terns Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Marquette Asset Management LLC (0.07%). Company insiders that own Terns Pharmaceuticals stock include James E Flynn and Vivo Capital Fund Viii, LP.
View institutional ownership trends for Terns Pharmaceuticals
.

Which major investors are buying Terns Pharmaceuticals stock?

TERN stock was bought by a variety of institutional investors in the last quarter, including Marquette Asset Management LLC. Company insiders that have bought Terns Pharmaceuticals stock in the last two years include James E Flynn, and Vivo Capital Fund Viii, LP.
View insider buying and selling activity for Terns Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Terns Pharmaceuticals?

Shares of TERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Terns Pharmaceuticals' stock price today?

One share of TERN stock can currently be purchased for approximately $5.60.

How much money does Terns Pharmaceuticals make?

Terns Pharmaceuticals has a market capitalization of $141.50 million. The company earns $-40.05 million in net income (profit) each year or ($5.43) on an earnings per share basis.

How many employees does Terns Pharmaceuticals have?

Terns Pharmaceuticals employs 30 workers across the globe.

What is Terns Pharmaceuticals' official website?

The official website for Terns Pharmaceuticals is www.ternspharma.com.

Where are Terns Pharmaceuticals' headquarters?

Terns Pharmaceuticals is headquartered at 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404.

How can I contact Terns Pharmaceuticals?

Terns Pharmaceuticals' mailing address is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. The company can be reached via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.